It is generally accepted that chemical control of insects at some level will be necessary for the preservation of human health and for agricultural productivity in the foreseeable future. If we are to meet these health and productivity standards while protecting the environment and man from potentially dangerous pesticides, we must a) develop safe, biodegradable pest control agents, b) understand xenobiotic metabolism in target and nontarget organisms, and c) develop rapid, sensitive analytical methods capable of detecting potentially dangerous xenobiotics. Thus, the long-term goal of this project is the safeguarding of human and environmental health by solving aspects of the above problems. I. We will develop new leads for environmentally acceptable insect control agents by investigating the critical events in the metamorphosis of our most destructive insect pests. THese leads can hopefully be exploited by both classical chemistry and genetic engineering. II. Since the epoxide moiety is the reactive center in some of the most dangerous toxins, mutagens and carcinogens known, we will investigate its metabolism in mammalian systems. Special attention will be paid to the induction and inhibition of these systems. Using selective substrates, inducers and inhibitors, we will work toward the development of a predictive model of epoxide catabolism. III. Finally, we will evaluate immunochemical technology as a technique capable of rapidly and inexpensively analyzing both classical and innovative pesticides.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES002710-12
Application #
3250025
Study Section
Toxicology Subcommittee 2 (TOX)
Project Start
1980-12-01
Project End
1992-11-30
Budget Start
1991-12-01
Budget End
1992-11-30
Support Year
12
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Earth Sciences/Natur
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475
Yang, Yang-Ming; Sun, Dong; Kandhi, Sharath et al. (2018) Estrogen-dependent epigenetic regulation of soluble epoxide hydrolase via DNA methylation. Proc Natl Acad Sci U S A 115:613-618
Stevens, Jacqueline S; Gray, Mary C; Morisseau, Christophe et al. (2018) Endocervical and Neutrophil Lipoxygenases Coordinate Neutrophil Transepithelial Migration to Neisseria gonorrhoeae. J Infect Dis 218:1663-1674
Bastan, Idil; Ge, Xiao Na; Dileepan, Mythili et al. (2018) Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation. J Leukoc Biol 104:109-122
Lakkappa, Navya; Krishnamurthy, Praveen T; Yamjala, Karthik et al. (2018) Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development. J Pharm Biomed Anal 149:457-464
Guedes, A G P; Aristizabal, F; Sole, A et al. (2018) Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis. J Vet Pharmacol Ther 41:230-238
?ertíková Chábová, V?ra; Kujal, Petr; Škaroupková, Petra et al. (2018) Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res 43:329-349

Showing the most recent 10 out of 450 publications